KRED Biocatalysis for Beta-3 Agonist and Intermediate Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for preparing beta-3 agonists and intermediates are inefficient and costly, lacking an economical and effective method using biocatalysts.
Innovation Solution
A multiple-step synthetic process utilizing ketoreductase (KRED) enzymes for converting compounds I-3 to I-7 through various reactions, including reduction, coupling, and cyclization, with specific catalysts and conditions to optimize efficiency and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional chemical synthesis methods are used for preparing beta-3 agonists and intermediates, then the process can proceed with standard chemical reagents and conditions, but the process is inefficient and costly
Solution Approach 1:
The patent replaces conventional chemical synthesis methods with biocatalytic methods using engineered ketoreductase enzymes. This substitution of biological systems for chemical systems enables asymmetric reduction reactions with high stereoselectivity, improving both efficiency and reducing costs by eliminating the need for complex chiral resolution steps and expensive chiral reagents typically required in conventional synthesis
Solution Approach 2:
The patent employs protein engineering techniques to optimize the ketoreductase enzyme parameters, including improving enzyme stability, activity, and stereoselectivity through site-directed mutagenesis. By changing the biological parameters of the catalyst (enzyme structure and function), the process achieves higher productivity and lower manufacturing costs compared to conventional approaches
2Manufacturing precision
If biocatalytic methods using ketoreductase enzymes are employed, then efficiency and selectivity are enhanced, but the process requires optimization of multiple reaction parameters and conditions
Solution Approach 1:
The patent uses engineered ketoreductase enzymes as biocatalytic intermediaries to mediate the asymmetric reduction of ketone substrates. These enzymes serve as highly selective intermediaries that convert prochiral ketones into chiral alcohols with high enantiomeric excess, simplifying the overall process by eliminating the need for complex chiral auxiliaries or resolution steps while maintaining high manufacturing precision
Solution Approach 2:
The patent develops a versatile biocatalytic platform using ketoreductase enzymes that can be applied to multiple substrates and reaction types. The engineered enzymes demonstrate broad substrate scope and can perform various asymmetric reduction reactions under different conditions, reducing process complexity by providing a universal solution rather than requiring separate optimized processes for each transformation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high yield and selectivity in producing beta-3 agonists and intermediates, enhancing efficiency and reducing costs by leveraging biocatalytic methods.
Implementation Method 1
reducing compound I-3 in the presence of a KRED enzyme to produce compound I-4
Data Source
AI summary
The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.